These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3401284)

  • 21. Sequence of fibrinogen proteolysis and platelet release after intrauterine infusion of hypertonic saline.
    Nossel HL; Wasser J; Kaplan KL; LaGamma KS; Yudelman I; Canfield RE
    J Clin Invest; 1979 Nov; 64(5):1371-8. PubMed ID: 500818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of heparin bonding on catheter-induced fibrin formation and platelet activation.
    Nichols AB; Owen J; Grossman BA; Marcella JJ; Fleisher LN; Lee MM
    Circulation; 1984 Nov; 70(5):843-50. PubMed ID: 6237807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
    Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
    Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrinogen Manchester: identification of an abnormal fibrinopeptide A with a C-terminal arginine leads to histidine substitution.
    Southan C; Kehl M; Henschen A; Lane DA
    Br J Haematol; 1983 May; 54(1):143-51. PubMed ID: 6849832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decrease of fibrinogen in patients with peripheral atherosclerotic disease by ticlopidine.
    Randi ML; Mares M; Fabris F; Tison T; Barbone E; Girolami A
    Arzneimittelforschung; 1991 Apr; 41(4):414-6. PubMed ID: 1859515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct analysis of plasma fibrinogen-derived fibrinopeptides by high-performance liquid chromatography: investigation of nine congenital fibrinogen abnormalities.
    Southan C; Thompson E; Lane DA
    Br J Haematol; 1987 Apr; 65(4):469-73. PubMed ID: 3580304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delayed release of an abnormal fibrinopeptide A from fibrinogen Manchester: effect of the A alpha 16 Arg leads to His substitution upon fibrin monomer polymerization and the immunological crossreactivity of the peptide.
    Lane DA; Southan C; Ireland H; Thompson E; Kehl M; Henschen A
    Br J Haematol; 1983 Apr; 53(4):587-97. PubMed ID: 6830702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hypercoagulation and recurrence of cerebral infarct].
    Landi GL; Anzalone N; Morabito A; D'Angelo A; Mannucci PM
    G Clin Med; 1989; 70(6-7):415-6, 418-9. PubMed ID: 2527773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A global platelet test of thrombosis and thrombolysis detects a prothrombotic state in some patients with non-insulin dependent diabetes and in some patients with stroke.
    Nakajima S; Noguchi T; Taka T; Ueda T; Kaizu K; Fukamizu M; Fujita S; Tabuchi M; Yamamoto J
    Platelets; 2000 Dec; 11(8):459-66. PubMed ID: 11177445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs.
    Bo M; Bonino F; Neirotti M; Gottero M; Pernigotti L; Molaschi M; Fabris F
    Angiology; 1991 Feb; 42(2):106-13. PubMed ID: 2006757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibrinopeptide-A in diabetes mellitus. Relation to levels of blood glucose, fibrinogen disappearance, and hemodynamic changes.
    Jones RL
    Diabetes; 1985 Sep; 34(9):836-43. PubMed ID: 4029510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Plasma fibrinogen as a cardiovascular risk factor].
    Naito M; Hayashi T; Iguchi A
    Nihon Ronen Igakkai Zasshi; 1994 Mar; 31(3):213-8. PubMed ID: 8207872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A kinetic method for characterization of heterogenous fibrinogen and its application to fibrinogen Grand Rapids, a congenital dysfibrinogenemia.
    Higgins DL; Lewis SD; Penner JA; Shafer JA
    Thromb Haemost; 1982 Oct; 48(2):182-6. PubMed ID: 6217579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bezafibrate retard in type II diabetic patients: effects on hemostasis and glucose homeostasis.
    Mikhailidis DP; Mathur S; Barradas MA; Dandona P
    J Cardiovasc Pharmacol; 1990; 16 Suppl 9():platelet inhib/pd/ad/ae. PubMed ID: 1710742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abnormalities of blood coagulation in patients with cancer. Fibrinopeptide A generation and tumor growth.
    Rickles FR; Edwards RL; Barb C; Cronlund M
    Cancer; 1983 Jan; 51(2):301-7. PubMed ID: 6821818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
    Branchi A; Rovellini A; Sommariva D; Gugliandolo AG; Fasoli A
    Thromb Haemost; 1993 Aug; 70(2):241-3. PubMed ID: 8236126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platelet aggregation occurs in congenital afibrinogenaemia despite the absence of fibrinogen or its fragments in plasma and platelets, as demonstrated by immunoenzymology.
    Soria J; Soria C; Borg JY; Mirshahi M; Piguet H; Tron P; Fessard C; Caen JP
    Br J Haematol; 1985 Jul; 60(3):503-14. PubMed ID: 3893523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bezafibrate retard in patients with insulin-dependent diabetes: effect on serum lipoproteins, fibrinogen, and glycemic control.
    Durrington PN; Winocour PH; Bhatnagar D
    J Cardiovasc Pharmacol; 1990; 16 Suppl 9():S30-4. PubMed ID: 1710743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
    Ericsson CG; Hamsten A; Nilsson J; Grip L; Svane B; de Faire U
    Lancet; 1996 Mar; 347(9005):849-53. PubMed ID: 8622389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperfibrinogenemia is an independent risk factor for atherosclerotic renal artery stenosis.
    Park JS; Park JH; Kang JY; Yang WS; Kim SB; Park SW; Park SJ
    Am J Nephrol; 1999; 19(6):649-54. PubMed ID: 10592358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.